Dr. Chen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2002 Holcombe Blvd
Houston, TX 77030Phone+1 713-791-1414
Education & Training
Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2015 - 2017- Baylor College of MedicineResidency, Internal Medicine, 2012 - 2015
Indiana University School of MedicineClass of 2012
Certifications & Licensure
TX State Medical License 2017 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Clinical Trials
- A Study of PCSK9 Inhibitor AK102 in Healthy Subjects Start of enrollment: 2018 May 09
- A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis Start of enrollment: 2018 Jan 09
Publications & Presentations
PubMed
- 90 citationsA single-cell RNA-seq atlas of Schistosoma mansoni identifies a key regulator of blood feeding.George R Wendt, Lu Zhao, Rui Chen, Chenxi Liu, Anthony J. O’Donoghue
Science. 2020-09-25 - 63 citationsA nonhuman primate model of inherited retinal diseaseAla Moshiri, Rui Chen, Soohyun Kim, R. Alan Harris, Yumei Li
The Journal of Clinical Investigation. 2019-02-01 - 123 citationsComprehensive molecular diagnosis of 179 Leber congenital amaurosis and juvenile retinitis pigmentosa patients by targeted next generation sequencingXia Wang, Hui Wang, Vincent Sun, Han Fang Tuan, Vafa Keser
Journal of Medical Genetics. 2013-10-01
Journal Articles
- Microfluidic Cell Deformability Assay for Rapid and Efficient Kinase Screening with the CRISPR‐Cas9 SystemRui Chen, Xin Han, Angewandte Chemie
Press Mentions
NT/ Nanoparticles Create Heat from Light to Manipulate Electrical Activity in NeuronsJuly 26th, 2021
A Genome-Scale CRISPR Cas9 Dropout Screen Identifies Synthetically Lethal Targets in SRC-3 Inhibited Cancer CellsMarch 25th, 2021- Vizgen Debuts Next Generation Genomics Platform at AGBTMarch 1st, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
